Durvalumab

**Durvalumab**
	; Durvalumab (tshiò-li̍k sik) kah PD-L1 ho̍k-ha̍p ê khòng-guân kiat-ha̍p phìnn-tsat [en] (hún-âng sik). PDB: 5X8M.
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	CD274
Clinical data
Trade names	Imfinzi
Synonyms	MEDI4736, MEDI-4736
AHFS/Drugs.com	Monograph
MedlinePlus	a617030
data	US DailyMed: Durvalumab;
Pregnancy; category	AU: D ; ;
Routes of; administration	Tsīng-me̍h tī-liâu [en]
ATC code	L01FF03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Identifiers
CAS Number	1428935-60-7;
PubChem CID	249565666;
IUPHAR/BPS	7985;
DrugBank	DB11714;
ChemSpider	none;
UNII	28X28X9OKV;
KEGG	D10808;
Chemical and physical data
Formula	C6502H10018N1742O2024S42
Molar mass	146,322.36 g·mol−1

Durvalumab (piau-pà PD-L1)^[6] í Imfinzi phín-pâi siau-siū, sī FDA phue-tsún ê gâm-tsìng bián-i̍k liâu-huat, iû Medimmune/AstraZeneca sóo khai-huat.^[7]Durvalumab sī tsi̍t-t-tsióng jîn-luī bián-i̍k kiû-nn̄g-pe̍h G1 kappa (IgG1κ) tuann clone khòng-thé, ē-tàng tsóo-tn̄g tîng-sū-sìng sè-pau sí-bông phuè-thé 1 (PD-L1) hām PD-1 (CD279) ê hōo-siong tsok-iōng. Durvalumab sī tsi̍t-tsióng bián-i̍k kiám-tsa-tiám ik-tsè-tsè io̍h-bu̍t.^[8]

Tsù-kái[siu-kái | kái goân-sí-bé]

↑ "Durvalumab (Imfinzi) Use During Pregnancy". Drugs.com. 30 August 2019. goân-loē-iông tī 29 August 2021 hőng khó͘-pih. 7 February 2020 khòaⁿ--ê.
↑ "Imfinzi (AstraZeneca Pty Ltd)". Therapeutic Goods Administration (TGA). 5 December 2022. goân-loē-iông tī 18 March 2023 hőng khó͘-pih. 9 April 2023 khòaⁿ--ê.
↑ "Regulatory Decision Summary - Imfinzi". Health Canada. 23 October 2014. goân-loē-iông tī 7 June 2022 hőng khó͘-pih. 6 September 2022 khòaⁿ--ê.
↑ "Imfinzi EPAR". European Medicines Agency (EMA). 17 September 2018. goân-loē-iông tī 28 August 2021 hőng khó͘-pih. 30 September 2020 khòaⁿ--ê.
↑ "Imfinzi- durvalumab injection, solution". DailyMed. 5 June 2020. goân-loē-iông tī 28 August 2021 hőng khó͘-pih. 30 September 2020 khòaⁿ--ê.
↑ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information. 28 (4). goân-loē-iông (PDF) tī 28 August 2021 hőng khó͘-pih. 6 September 2022 khòaⁿ--ê.
↑ "Durvalumab (Imfinzi)". U.S. Food and Drug Administration (FDA). goân-loē-iông tī 8 May 2017 hőng khó͘-pih. 2017-05-06 khòaⁿ--ê.
↑ Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.

Tsham-ua̍t[siu-kái | kái goân-sí-bé]

CTLA-4
LAG-3
Atezolizumab (Tecentriq; target PD-L1)
Avelumab (Bavencio; target PD-L1)
Pembrolizumab (Keytruda; target PD-1)
Nivolumab (Opdivo; target PD-1)
Cemiplimab (Libtayo; target PD-1)
Ipilimumab (Yervoy; CTLA-4 inhibitor)
Tremelimumab (Imjuno; CTLA-4 inhibitor)
Relatlimab (LAG-3 inhibitor)

Guā-pōo liân-kiat[siu-kái | kái goân-sí-bé]

"Durvalumab". NCI Drug Dictionary. National Cancer Institute.
"Durvalumab". National Cancer Institute. 5 May 2017.
Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitors and Their Side Effects
【2018諾貝爾生醫獎】癌症免疫療法新突破

[Drugs.com_pregnancy-1] "Durvalumab (Imfinzi) Use During Pregnancy". Drugs.com. 30 August 2019. goân-loē-iông tī 29 August 2021 hőng khó͘-pih. 7 February 2020 khòaⁿ--ê.

[2] "Imfinzi (AstraZeneca Pty Ltd)". Therapeutic Goods Administration (TGA). 5 December 2022. goân-loē-iông tī 18 March 2023 hőng khó͘-pih. 9 April 2023 khòaⁿ--ê.

[3] "Regulatory Decision Summary - Imfinzi". Health Canada. 23 October 2014. goân-loē-iông tī 7 June 2022 hőng khó͘-pih. 6 September 2022 khòaⁿ--ê.

[Imfinzi_EPAR-4] "Imfinzi EPAR". European Medicines Agency (EMA). 17 September 2018. goân-loē-iông tī 28 August 2021 hőng khó͘-pih. 30 September 2020 khòaⁿ--ê.

[Imfinzi_FDA_label-5] "Imfinzi- durvalumab injection, solution". DailyMed. 5 June 2020. goân-loē-iông tī 28 August 2021 hőng khó͘-pih. 30 September 2020 khòaⁿ--ê.

[6] World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information. 28 (4). goân-loē-iông (PDF) tī 28 August 2021 hőng khó͘-pih. 6 September 2022 khòaⁿ--ê.

[7] "Durvalumab (Imfinzi)". U.S. Food and Drug Administration (FDA). goân-loē-iông tī 8 May 2017 hőng khó͘-pih. 2017-05-06 khòaⁿ--ê.

[:0-8] Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.

[1]

[2]

[3]

[5]

[4]

[6]

[7]

[8]